Concepedia

Author

Giulia Benevolo

Azienda Ospedaliera Citta' della Salute e della Scienza di TorinoORCID

Also Known As

Benevolo, G., G Benevolo, G. Benevolo, Giulia Benevolo

268

Publications

6.9K

Citations

40

H-Index

66

Concepts

All Affiliations

Azienda Ospedaliera Citta' della Salute e della Scienza di TorinoIstituti di Ricovero e Cura a Carattere ScientificoFondazione IRCCS Ca' Granda Ospedale Maggiore PoliclinicoUniversity of CataniaUniversity of Verona
GB

About

Giulia Benevolo is an author at Azienda Ospedaliera Citta' della Salute e della Scienza di Torino specializing in medicine, oncology, and hematology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

21

30

2.1K

2

Health Sciences

7

7

326

3

Public Health

2

2

109

4

Blood Transplantation

2

2

189

5

Nursing

1

1

21

Giulia Benevolo

×

84

Publications

6.1K

Citations

38

H-Index

YearCitations

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

Antonio Palumbo, Davide Rossi, Maide Cavalli,

Journal of Clinical Oncology

2010

424

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

Alessandra Larocca, Davide Rossi, Maide Cavalli,

Blood

2010

379

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç,

The Lancet Haematology

2020

377

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial

Antonio Palumbo, Sara Bringhen, Anna Marina Liberati,

Blood

2008

357

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

Francesco Passamonti, Toni Giorgino, Barbara Mora,

Leukemia

2017

323

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

Antonio Palumbo, Michèle Cavo, Elena Zamagni,

Journal of Clinical Oncology

2011

320

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study

Francesco Passamonti, Martin Grießhammer, Francesca Palandri,

The Lancet Oncology

2016

245

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival

Antonio Palumbo, Sara Bringhen, Alessandra Larocca,

Journal of Clinical Oncology

2014

210

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

Antonio Palumbo, Maria Teresa Ambrosini, Giulia Benevolo,

Blood

2006

181

Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients

Antonio Palumbo, Francesca Gay, Patrizia Falco,

Journal of Clinical Oncology

2010

174

Page 1